Spiro eIF2B Activator Compound for ALS Protein Synthesis Recovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently no cure for Amyotrophic Lateral Sclerosis (ALS) and no effective treatment methods that can stop or reverse the progression of the disease, which is characterized by motor neuron death and protein-folding homeostasis imbalance.
Innovation Solution
A compound that activates eIF2B to weaken the integrated stress response (ISR) in cells, promoting normal protein synthesis and potentially alleviating neurodegenerative diseases such as ALS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the integrated stress response (ISR) is activated in response to protein-folding stress, then protein homeostasis is restored through gene expression reprogramming, but long-term memory formation is inhibited and cognitive function deteriorates
Solution Approach 1:
The patent uses ISRIB as a mediator compound that specifically targets eIF2B to modulate the ISR pathway. ISRIB acts as an intermediary substance that can selectively inhibit eIF2B activity, thereby reducing ISR activation while preserving other cellular functions. This allows the system to maintain protein homeostasis through alternative mechanisms without blocking memory formation processes.
Solution Approach 2:
The patent changes the biochemical parameters of the ISR pathway by introducing compounds that modify eIF2B activity levels. By adjusting the activity parameter of eIF2B through pharmacological intervention, the system can achieve a balanced state where protein homeostasis is maintained through other UPR mechanisms while cognitive functions are preserved.
2Reliability
If eIF2B activators such as ISRIB are used to restore protein translation, then protein synthesis is normalized and UPR transcription is reverted to basal levels, but the complexity of the treatment regimen increases
Solution Approach 1:
The patent employs compounds that enable the cell's own eIF2B enzyme to restore protein synthesis autonomously. The treatment mechanism leverages the cell's intrinsic translational machinery, allowing it to self-correct protein homeostasis imbalances without requiring external complex intervention systems. The compound simply needs to be present to trigger the endogenous repair mechanism.
3Ease of operation
If current ALS treatment methods are used, then some symptomatic relief may be achieved, but the disease progression cannot be stopped or reversed
Solution Approach 1:
The patent applies preliminary action by using eIF2B modulators to prevent the activation of harmful ISR pathways before they can cause neuronal damage. By maintaining eIF2B in an appropriate inactive state, the treatment preemptively protects against protein-misfolding stress and prevents the cascade of events leading to motor neuron death, rather than merely treating symptoms after they manifest.
Data Source
AI summary
Provided are a compound of formula 0, a stereoisomer thereof, a tautomer thereof, a geometric isomer thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a polymorph thereof, a solvate thereof, a hydrate thereof, an N-oxide thereof, an isotopically labeled compound thereof, a metabolite thereof, an ester thereof, a prodrug thereof, and a pharmaceutically acceptable salt thereof. In formula 0, ring B is a 5- to 10-membered spiro ring or a 5- to 10-membered spiro heterocyclic ring. The 5- to 10-membered spiro ring and the 5- to 10-membered spiro heterocyclic ring are optionally substituted with 1-5 R1F. The compound can significantly weaken the integrated stress response (ISR) of cells and activate the activity of eIF2B, so that proteins in the cells tend to be synthesized normally.